Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Caloric Restriction Slows Age-Related Loss of Neurons by Activating SIRT1

By BiotechDaily International staff writers
Posted on 06 Jun 2013
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Caloric restriction (CR), a dietary regimen known to promote lifespan by retarding the onset of age-dependent diseases, has been found to slow the progressive loss of neurons associated with impaired cognitive capacity by activating the enzyme sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1).

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) speculated that since aging is the greatest risk factor for neurodegeneration in the brain, CR might slow the progressive loss of neurons. To explore this possibility they used a genetically engineered mouse model that allowed for temporally and spatially controlled onset of neurodegeneration. These animals were fed a diet decreased by 30% from the normal mouse diet for three months.

Results published in the May 22, 2013, issue of the Journal of Neuroscience revealed that CR significantly delayed the onset of neurodegeneration and synaptic loss and dysfunction, and thereby preserved cognitive capacities.

“We not only observed a delay in the onset of neurodegeneration in the calorie-restricted mice, but the animals were spared the learning and memory deficits of mice that did not consume reduced-calorie diets,” said senior author Dr. Li-Huei Tsai, professor of brain and cognitive sciences at the Massachusetts Institute of Technology. “The question now is whether this type of treatment will work in other animal models, whether it is safe for use over time, and whether it only temporarily slows down the progression of neurodegeneration or stops it altogether



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.